首页> 外文期刊>Genes and Diseases >Known drugs and small molecules in the battle for COVID-19 treatment
【24h】

Known drugs and small molecules in the battle for COVID-19 treatment

机译:Covid-19治疗的争斗中的已知药物和小分子

获取原文
           

摘要

COVID-19 has been declared a pandemic by the World Health Organization on March 11th and since then more than 3 million cases and a quarter million deaths have occurred due to it. The urge to find a resultful treatment or cure is now pressing more than any other time since the outbreak of the pandemic. Researchers all over the world from different fields of expertise are trying to find the most suitable drugs, that are already known to treat other diseases, and could tackle the process of SARS-CoV2 through which it invades and replicates in human cells. Here, we discuss five of the most promising drugs that can potentially play a major role in the treatment of COVID-19. While nicotine and ivermectin may be blocking transport abilities of the virus or its components, famotidine, remdesivir and chloroquine in combination with zinc ions can deactivate important enzymes needed for the replication of the virus. While clinical trials for some of these drugs have already started, it is common knowledge that lack of organization between countries, institutes and hospitals might slow down the whole process for an official treatment based in wide, randomized, placebo controlled trials.
机译:Covid-19于3月11日被世界卫生组织宣布大流行,从那时起,由于它而发生了超过300万个案件和四分之一的死亡。找到产生的待遇或治疗的冲动现在是自大流行爆发以来的任何其他时间。来自世界各地的研究人员来自不同的专业领域正在努力寻找最合适的药物,这些药物已经熟知治疗其他疾病,并且可以解决SARS-CoV2的过程,通过其侵入和重复人体细胞。在这里,我们讨论了最有希望的五种药物,这些药物可能在Covid-19的治疗中发挥重要作用。虽然尼古丁和伊维菌素可以阻塞病毒的传输能力或其组分,但与锌离子组合的Famotidine,Remdesivir和氯喹可以使得能够反应病毒复制所需的重要酶。虽然一些这些药物的临床试验已经开始,但常识是缺乏各国,机构和医院之间的组织可能会减缓整个过程,这是基于广泛,随机的安慰剂对照试验的官方治疗。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号